Form 8-K - Current report:
SEC Accession No. 0000950170-25-077377
Filing Date
2025-05-27
Accepted
2025-05-27 07:32:57
Documents
16
Period of Report
2025-05-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20250527.htm   iXBRL 8-K 109100
2 EX-4.1 lxeo-ex4_1.htm EX-4.1 161768
3 EX-4.2 lxeo-ex4_2.htm EX-4.2 175506
4 EX-10.1 lxeo-ex10_1.htm EX-10.1 604518
5 EX-10.2 lxeo-ex10_2.htm EX-10.2 204755
6 EX-99.1 lxeo-ex99_1.htm EX-99.1 24715
7 GRAPHIC img46940271_0.jpg GRAPHIC 194235
  Complete submission text file 0000950170-25-077377.txt   1803384

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250527.xsd EX-101.SCH 25989
18 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250527_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 25984202
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)